company background image
CCXI

ChemoCentryx NasdaqGS:CCXI Stock Report

Last Price

US$51.99

Market Cap

US$3.7b

7D

0.1%

1Y

50.4%

Updated

23 Oct, 2022

Data

Company Financials +

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.
CCXI fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

CCXI Stock Overview

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States.

ChemoCentryx, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ChemoCentryx
Historical stock prices
Current Share PriceUS$51.99
52 Week HighUS$52.00
52 Week LowUS$14.95
Beta1.23
1 Month Change0.41%
3 Month Change134.51%
1 Year Change50.39%
3 Year Change558.10%
5 Year Change642.71%
Change since IPO372.64%

Recent News & Updates

ChemoCentryx shareholders approve $4.7B merger with Amgen

Oct 18

ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M

Aug 09

Recent updates

ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?

Jun 06
ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?

ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?

Feb 11
ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?

Analysts Are Betting On ChemoCentryx, Inc. (NASDAQ:CCXI) With A Big Upgrade This Week

Jan 21
Analysts Are Betting On ChemoCentryx, Inc. (NASDAQ:CCXI) With A Big Upgrade This Week

Is ChemoCentryx (NASDAQ:CCXI) Using Debt In A Risky Way?

Oct 09
Is ChemoCentryx (NASDAQ:CCXI) Using Debt In A Risky Way?

Time To Worry? Analysts Just Downgraded Their ChemoCentryx, Inc. (NASDAQ:CCXI) Outlook

Aug 11
Time To Worry? Analysts Just Downgraded Their ChemoCentryx, Inc. (NASDAQ:CCXI) Outlook

ChemoCentryx, Inc.'s (NASDAQ:CCXI) Intrinsic Value Is Potentially 34% Above Its Share Price

Jul 11
ChemoCentryx, Inc.'s (NASDAQ:CCXI) Intrinsic Value Is Potentially 34% Above Its Share Price

ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Jun 15
ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

When Will ChemoCentryx, Inc. (NASDAQ:CCXI) Become Profitable?

Mar 03
When Will ChemoCentryx, Inc. (NASDAQ:CCXI) Become Profitable?

ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Feb 04
ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Have ChemoCentryx, Inc. (NASDAQ:CCXI) Insiders Been Selling Their Stock?

Dec 31
Have ChemoCentryx, Inc. (NASDAQ:CCXI) Insiders Been Selling Their Stock?

Analyst Forecasts Just Became More Bearish On ChemoCentryx, Inc. (NASDAQ:CCXI)

Dec 23
Analyst Forecasts Just Became More Bearish On ChemoCentryx, Inc. (NASDAQ:CCXI)

Did The Underlying Business Drive ChemoCentryx's (NASDAQ:CCXI) Lovely 934% Share Price Gain?

Dec 13
Did The Underlying Business Drive ChemoCentryx's (NASDAQ:CCXI) Lovely 934% Share Price Gain?

Are Investors Undervaluing ChemoCentryx, Inc. (NASDAQ:CCXI) By 25%?

Nov 22
Are Investors Undervaluing ChemoCentryx, Inc. (NASDAQ:CCXI) By 25%?

Shareholder Returns

CCXIUS BiotechsUS Market
7D0.1%0.4%1.3%
1Y50.4%-14.4%-18.5%

Return vs Industry: CCXI exceeded the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: CCXI exceeded the US Market which returned -23.7% over the past year.

Price Volatility

Is CCXI's price volatile compared to industry and market?
CCXI volatility
CCXI Average Weekly Movement31.3%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: CCXI is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 31% a week.

Volatility Over Time: CCXI's weekly volatility has increased from 18% to 31% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1996178n/ahttps://www.chemocentryx.com

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis.

ChemoCentryx, Inc. Fundamentals Summary

How do ChemoCentryx's earnings and revenue compare to its market cap?
CCXI fundamental statistics
Market CapUS$3.74b
Earnings (TTM)-US$133.09m
Revenue (TTM)US$37.28m

100.3x

P/S Ratio

-28.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CCXI income statement (TTM)
RevenueUS$37.28m
Cost of RevenueUS$71.86m
Gross Profit-US$34.58m
Other ExpensesUS$98.51m
Earnings-US$133.09m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.85
Gross Margin-92.76%
Net Profit Margin-357.01%
Debt/Equity Ratio10.5%

How did CCXI perform over the long term?

See historical performance and comparison